{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"342"}]}],"title":"Deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"177"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"}]}],"title":"Drug related SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"353"}]}],"title":"Drug related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"51"}]}],"title":"Discontinued due to Drug-related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"82"}]}],"title":"Discontinued due to AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"398"},{"groupId":"OG001","value":"387"}]}],"title":"Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"397"}],"units":"Participants"}],"description":"Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants; all participants who received at least one dose of nivolumab or everolimus","reportingStatus":"POSTED","timeFrame":"Day of first dose to 30 days post study completion (approximately 106 months)","title":"Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}